Which has higher earnings & valuation, SEER or HBIO?

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $16.58M 6.71 -$73.60M -$1.22 N/A Harvard Bioscience $86.55M 0.42 -$56.70M -$2.31 N/A

Is SEER or HBIO more profitable?

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% Harvard Bioscience -11.86% -33.13% -4.80%

Do analysts prefer CSBR or HBIO?

Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 14.56%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Harvard Bioscience (HBIO) Competitors

$7.90 +0.25 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.89 -0.01 (-0.13%)

As of 07:55 PM Eastern

Compare

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

Should you buy Harvard Bioscience stock or one of its competitors? Harvard Bioscience's main competitors and comparable companies include Quanterix (QTRX), Seer (SEER), Nautilus Biotechnology (NAUT), Rapid Micro Biosystems (RPID), and Champions Oncology (CSBR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Quanterix?

Harvard Bioscience (NASDAQ:HBIO) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

In the previous week, Harvard Bioscience and Harvard Bioscience both had 1 articles in the media. Harvard Bioscience's average media sentiment score of 1.89 equaled Quanterix'saverage media sentiment score.

Company	Overall Sentiment
Harvard Bioscience	Very Positive
Quanterix	Very Positive

Harvard Bioscience has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Harvard Bioscience has a net margin of -11.86% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Quanterix	-80.25%	-26.09%	-19.03%

Harvard Bioscience has higher earnings, but lower revenue than Quanterix. Harvard Bioscience is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Harvard Bioscience currently has a consensus target price of $6.75, indicating a potential downside of 14.56%. Quanterix has a consensus target price of $3.00, indicating a potential upside of 13.64%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Harvard Bioscience beats Quanterix on 8 of the 14 factors compared between the two stocks.

How does Harvard Bioscience compare to Seer?

Seer (NASDAQ:SEER) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

In the previous week, Seer had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Seer and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.89 beat Seer's score of 0.78 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Seer	Positive
Harvard Bioscience	Very Positive

Seer has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Seer currently has a consensus price target of $4.00, indicating a potential upside of 99.00%. Harvard Bioscience has a consensus price target of $6.75, indicating a potential downside of 14.56%. Given Seer's stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	6.71	-$73.60M	-$1.22	N/A
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A

75.2% of Seer shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Summary

Seer beats Harvard Bioscience on 9 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, Nautilus Biotechnology and Nautilus Biotechnology both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.89 equaled Harvard Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Harvard Bioscience	Very Positive

Nautilus Biotechnology has a net margin of 0.00% compared to Harvard Bioscience's net margin of -11.86%. Harvard Bioscience's return on equity of -33.13% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 342.43%. Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 14.56%. Given Nautilus Biotechnology's higher probable upside, research analysts clearly believe Nautilus Biotechnology is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nautilus Biotechnology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Harvard Bioscience has higher revenue and earnings than Nautilus Biotechnology. Harvard Bioscience is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A

Summary

Harvard Bioscience beats Nautilus Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Harvard Bioscience (NASDAQ:HBIO) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Harvard Bioscience currently has a consensus price target of $6.75, indicating a potential downside of 14.56%. Rapid Micro Biosystems has a consensus price target of $6.00, indicating a potential upside of 272.67%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Harvard Bioscience has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

In the previous week, Harvard Bioscience and Harvard Bioscience both had 1 articles in the media. Harvard Bioscience's average media sentiment score of 1.89 beat Rapid Micro Biosystems' score of 1.87 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Harvard Bioscience	Very Positive
Rapid Micro Biosystems	Very Positive

Rapid Micro Biosystems has lower revenue, but higher earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Rapid Micro Biosystems	$35.18M	2.30	-$47.12M	-$1.12	N/A

Harvard Bioscience has a net margin of -11.86% compared to Rapid Micro Biosystems' net margin of -145.56%. Harvard Bioscience's return on equity of -33.13% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by company insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Harvard Bioscience beats Rapid Micro Biosystems on 8 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Champions Oncology has higher earnings, but lower revenue than Harvard Bioscience. Champions Oncology is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.17	-$1.17M	-$0.08	N/A
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A

Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 14.56%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Champions Oncology had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.89 beat Champions Oncology's score of 1.51 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Harvard Bioscience	Very Positive

Champions Oncology has a net margin of -1.87% compared to Harvard Bioscience's net margin of -11.86%. Champions Oncology's return on equity of -27.48% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.87%	-27.48%	-3.84%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Champions Oncology and Harvard Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.83M	$10.23B	$7.31B	$12.78B
Dividend Yield	N/A	1.46%	2.53%	11.03%
P/E Ratio	-3.42	50.86	210.50	22.08
Price / Sales	0.42	111.27	630.29	95.53
Price / Cash	0.65	26.95	79.17	53.57
Price / Book	4.85	37.66	13.01	6.26
Net Income	-$56.70M	$56.67B	$3.46B	$348.07M
7 Day Performance	4.64%	0.62%	1.95%	1.40%
1 Month Performance	31.89%	10.52%	8.17%	4.59%
1 Year Performance	49.06%	27.44%	26.28%	17.05%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	1.2643 of 5 stars	$7.90 +3.3%	$6.75 -14.6%	+40.8%	$34.83M	$86.55M	N/A	490	Positive News
QTRX Quanterix	1.6121 of 5 stars	$2.68 -8.2%	$3.00 +11.9%	-42.9%	$126.74M	$138.90M	N/A	460	Positive News
SEER Seer	3.7368 of 5 stars	$2.02 -0.5%	$4.00 +98.0%	-2.9%	$111.06M	$13.75M	N/A	160
NAUT Nautilus Biotechnology	3.166 of 5 stars	$0.86 -2.9%	$4.00 +367.7%	+32.8%	$108.84M	$10K	N/A	130	Positive News
RPID Rapid Micro Biosystems	3.0168 of 5 stars	$1.56 +0.6%	$6.00 +284.6%	-36.7%	$78.25M	$33.59M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

How does Harvard Bioscience compare to Quanterix?

Summary

How does Harvard Bioscience compare to Seer?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Summary

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

How does Harvard Bioscience compare to Quanterix?

Does the media refer more to HBIO or QTRX?

Which has more volatility and risk, HBIO or QTRX?

Is HBIO or QTRX more profitable?

Which has preferable valuation and earnings, HBIO or QTRX?

Do insiders & institutionals have more ownership in HBIO or QTRX?

Do analysts rate HBIO or QTRX?

Summary

How does Harvard Bioscience compare to Seer?

Does the media favor SEER or HBIO?

Which has more risk & volatility, SEER or HBIO?

Do analysts recommend SEER or HBIO?

Which has higher earnings & valuation, SEER or HBIO?

Do insiders and institutionals believe in SEER or HBIO?

Is SEER or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Does the media favor NAUT or HBIO?

Is NAUT or HBIO more profitable?

Do analysts recommend NAUT or HBIO?

Do institutionals & insiders have more ownership in NAUT or HBIO?

Which has more volatility & risk, NAUT or HBIO?

Which has preferable earnings and valuation, NAUT or HBIO?

Summary

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Do analysts rate HBIO or RPID?

Which has more volatility & risk, HBIO or RPID?

Does the media refer more to HBIO or RPID?

Which has preferable valuation & earnings, HBIO or RPID?

Is HBIO or RPID more profitable?

Do insiders and institutionals have more ownership in HBIO or RPID?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Which has better valuation & earnings, CSBR or HBIO?

Do analysts prefer CSBR or HBIO?

Does the media prefer CSBR or HBIO?

Is CSBR or HBIO more profitable?

Do institutionals and insiders hold more shares of CSBR or HBIO?

Which has more risk and volatility, CSBR or HBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools